Detailed Information

Cited 37 time in webofscience Cited 44 time in scopus
Metadata Downloads

Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study

Authors
Yuen, Man-FungAhn, Sang HoonLee, Kwan SikUm, Soon HoCho, MongYoon, Seung KewLee, Jin-WooPark, Neung HwaKweon, Young-OhSohn, Joo HyunLee, JiyoonKim, Jeong-AeLai, Ching-LungHan, Kwang-Hyub
Issue Date
Mar-2015
Publisher
ELSEVIER SCIENCE BV
Keywords
Besifovir; LB80380; Entecavir; Viral suppression; Resistance; Safety
Citation
JOURNAL OF HEPATOLOGY, v.62, no.3, pp.526 - 532
Indexed
SCIE
SCOPUS
Journal Title
JOURNAL OF HEPATOLOGY
Volume
62
Number
3
Start Page
526
End Page
532
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8112
DOI
10.1016/j.jhep.2014.10.026
ISSN
0168-8278
Abstract
Background & Aims: We aimed to compare the viral suppression, safety and rate of drug resistance between besifovir (a new acyclic nucleotide analogue) and entecavir. Methods: Treatment-naive chronic hepatitis B patients receiving besifovir 90 mg (n = 31), 150 mg (n = 28) and entecavir 0.5 mg (n = 30) were monitored for liver biochemistry, viral serology, HBV DNA levels, development of drug resistance mutations, and adverse events throughout 96 weeks of treatment. Results: The mean decline of HBV DNA levels from baseline to week 96 were 5.29, 5.15, and 5.67 logs IU/ml for patients receiving besifovir 90 mg, 150 mg and entecavir 0.5 mg, respectively (p > 0.05). Undetectable HBV DNA (< 20 IU/ml) were achieved in 80.7%, 78.6%, and 80%; ALT normalization in 90.3%, 78.6%, and 93.3%; and loss of HBeAg in 20%, 21.4%, and 22.2% of patients respectively (all p > 0.05). One patient receiving besifovir 90 mg had a virological breakthrough due to drug non-compliance. No patient developed drug resistance mutations. Ten patients had serious adverse events, which were not related to the study medications. The most common side effect related to besifovir was carnitine depletion. Carnitine supplements were prescribed to 83.9% and 100% of patients, who had low carnitine level for any one time during follow-up, receiving besifovir 90 mg and 150 mg respectively. No patient had increased creatinine >0.5 mg/dl from baseline. Conclusions: Besifovir had the same antiviral property as compared to entecavir over 96 weeks of treatment for chronic hepatitis B patients. Besifovir was well tolerated and also had a good clinical safety profile. (C) 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE